{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2423","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"2.4","upperLimit":"29.2","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"The response rate (percentage) is the percent of patients whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients. Response rates (including complete and partial response) will be tested using Fisher's exact test","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo observation until disease progression.","id":"OG000","title":"Arm A (Observation)"},{"description":"Patients receive pemetrexed 500 mg/m2 IV over 10 minutes (or per institutional guidelines) every three weeks. Patients will continue treatment until disease progression or excess toxicity.","id":"OG001","title":"Arm B (Pemetrexed)"}],"paramType":"NUMBER","populationDescription":"One patient on the observation arm did not submit any follow-up forms and withdrew consent to all follow-up and thus excluded in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}